RecruitingPhase 4

PEG3350 vs Senna After Urogyn Surgery

United States254 participantsStarted 2025-04-23

Plain-language summary

The goal of this study is to evaluate whether polyethylene glycol 3350 (PEG3350) versus senna is better at relieving postoperative constipation after urogynecologic surgery. The main questions it aims to answer are: What number of patients taking PEG3350 have obstructed defecation syndrome (ODS), a form of constipation, vs those taking senna in the week after urogynecologic surgery? What patient-level and procedure-level characteristics are associated with postoperative ODS, in patients taking PEG3350 vs senna? participants will: Take their randomized medication daily for seven days after surgery Fill out an ODS questionnaire before and one week after surgery Complete a daily bowel diary for 7 days after surgery

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Inclusion criteria includes women scheduled for urogynecologic surgery for pelvic organ prolapse and/or stress urinary incontinence and at least 18 years old. Exclusion Criteria: * Exclusion criteria include undergoing concomitant bowel surgery (colonic resection, anal sphincter repair, rectovaginal fistula repair, rectopexy) or placement of a sacral neuromodulation device alone.

What they're measuring

Postoperative ODS in Patients Taking PEG3350 vs Senna

Timeframe: From enrollment to the end of treatment at 7 days after surgery.

Trial details

NCT IDNCT06825260

SponsorSt. Joseph's Health, New York

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-03

Contact for this trial

Keila S Muniz, MD

631-896-7937 keila.muniz@sjhsyr.org

View on ClinicalTrials.gov More Obstructive Defecation Syndrome trials